January 16, 2025 10:08 AM ESTUpdated 11:09 AM
News Briefing

Boehringer's schiz­o­phre­nia as­set fails Phase 3; GSK buys organoid biotech

ENDPOINTS

Plus, news about Ko­di­ak Sci­ences, Out­look Ther­a­peu­tics and Avac­ta:

Boehringer In­gel­heim re­ports Phase 3 schiz­o­phre­nia fail: The drug, icleper­tin,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

HHS blasts Boehringer's drug price case, re­veals new de­tails on Jar­diance talks

De­part­ing FDA com­mis­sion­er: 'We're los­ing the bat­tle on mis­in­for­ma­tion'

FDA re­jects Atara's cell ther­a­py for rare trans­plant com­pli­ca­tion, stock craters

Broad In­sti­tute pa­per of­fers po­ten­tial new frame­work for treat­ing Hunt­ing­ton’s dis­ease

Vac­cine patch start­up col­lects an ad­di­tion­al $16M to Se­ries A

A service from the Financial Times